Zelalem Eshete

Array ( [id] => 11443128 [patent_doc_number] => 20170044149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'PHARMACEUTICAL SALTS OF AN OREXIN RECEPTOR ANTAGONIST' [patent_app_type] => utility [patent_app_number] => 15/305246 [patent_app_country] => US [patent_app_date] => 2015-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9437 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421309 [patent_doc_number] => 20170029453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'BIS(PHOSPHINE)-CARBODICARBENE CATALYST COMPLEXES AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/302699 [patent_app_country] => US [patent_app_date] => 2015-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17222 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635611 [patent_doc_number] => 09353103 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Macrocyclic inhibitors of hepatitis C virus' [patent_app_type] => utility [patent_app_number] => 14/684649 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40258 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14684649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12112764 [patent_doc_number] => 09868744 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-16 [patent_title] => 'Heteroaromatic compounds and their use as dopamine D1 ligands' [patent_app_type] => utility [patent_app_number] => 15/305372 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56559 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325690 [patent_doc_number] => 20150210691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/681743 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80557 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12565809 [patent_doc_number] => 10017509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Macrocylic pyrimidine derivatives [patent_app_type] => utility [patent_app_number] => 15/300956 [patent_app_country] => US [patent_app_date] => 2015-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52221 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 988 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15300956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254150 [patent_doc_number] => 09926286 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Vortioxetine intermediate and synthesis process thereof' [patent_app_type] => utility [patent_app_number] => 15/126890 [patent_app_country] => US [patent_app_date] => 2015-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4844 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15126890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13856151 [patent_doc_number] => 10189784 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase [patent_app_type] => utility [patent_app_number] => 15/129815 [patent_app_country] => US [patent_app_date] => 2015-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17739 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 439 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15129815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10312494 [patent_doc_number] => 20150197496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/665879 [patent_app_country] => US [patent_app_date] => 2015-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17605 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14665879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11243622 [patent_doc_number] => 09469655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-18 [patent_title] => 'Methods for the acylation of maytansinol' [patent_app_type] => utility [patent_app_number] => 14/660050 [patent_app_country] => US [patent_app_date] => 2015-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7066 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14660050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11382833 [patent_doc_number] => 20170008888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'HETEROCYCLIC COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 15/121282 [patent_app_country] => US [patent_app_date] => 2015-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57150 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15121282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10677869 [patent_doc_number] => 20160024014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => '5HT2C RECEPTOR MODULATORS' [patent_app_type] => utility [patent_app_number] => 14/629083 [patent_app_country] => US [patent_app_date] => 2015-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 27277 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10281574 [patent_doc_number] => 20150166569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/622446 [patent_app_country] => US [patent_app_date] => 2015-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 248745 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14622446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340379 [patent_doc_number] => 20150225384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS' [patent_app_type] => utility [patent_app_number] => 14/621887 [patent_app_country] => US [patent_app_date] => 2015-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17859 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155758 [patent_doc_number] => 09187514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same' [patent_app_type] => utility [patent_app_number] => 14/621119 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89379 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155758 [patent_doc_number] => 09187514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same' [patent_app_type] => utility [patent_app_number] => 14/621119 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89379 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155758 [patent_doc_number] => 09187514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same' [patent_app_type] => utility [patent_app_number] => 14/621119 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89379 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155758 [patent_doc_number] => 09187514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same' [patent_app_type] => utility [patent_app_number] => 14/621119 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89379 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10608086 [patent_doc_number] => 09328108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-03 [patent_title] => 'Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435' [patent_app_type] => utility [patent_app_number] => 14/616770 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6791 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14616770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10265886 [patent_doc_number] => 20150150884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'BROMODOMAIN INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/617448 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59076 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14617448 [rel_patent_id] =>[rel_patent_doc_number] =>)